Member Exclusive

Epigenetic modulator for cancer immunotherapy

4SC, an innovative German biotech company, is developing 4SC-202, a novel HDAC class I/LSD1 inhibitor for combination with cancer immunotherapy.

Go to the profile of Svetlana Hamm
Oct 10, 2016

Please sign in or register for FREE to view this content

Register to EpigenomicsNet – the epigenetics and epigenomics network

EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet. Start the conversation...